doc4th European Post-Chicago Melanoma/Skin Cancer Meeting
download 
Report Transcription
4th European Post-Chicago Melanoma/Skin Cancer Meeting
Congress Presidents Axel Hauschild, Kiel, Germany Claus Garbe, Tuebingen, Germany Final Program 4 th European Post-Chicago Melanoma/Skin Cancer Meeting Results and Interpretations of ASCO Presentations 2014: Interdisciplinary Global Conference on News in Melanoma/Skin Cancer June 26th–27th, 2014 Munich, Germany Leonardo Royal Hotel www.melanomaglobal2014.org Under the auspices of the European Association of Dermato-Oncology and ADO/DeCOG ERDGESCHOSS/GROUND FLOOR Terrasse/terrace R7 R6 R5 SpeakerPreviewRoom R3 künstlicher Wasserlauf/ artificial water point R4 Service R2 R1 Business Center Davidoff Lounge Lobby Lifts Registration Desk WC/ toilet Moosacher Straße 90 Reception Desk Einfahrt Tiefgarage/ access underground parking Foyer Service Terrasse/terrace Hoteleingang/ hotel entrance UNTERGESCHOSS/BASEMENT LEONARDO ROYAL HOTEL MUNICH FLOOR PLAN Back Office CONTENT WELCOME MESSAGE 03 FINAL PROGRAM AT A GLANCE 04 PROGRAM 06 Thursday, June 26th 06 Friday, June 27 th 08 CONGRESS FACULTY 13 SATELLITE SYMPOSIA OVERVIEW 15 GENERAL INFORMATION 18 SPONSORS 21 WELCOME MESSAGE Dear colleagues and friends, Since the first Post-Chicago Meeting on Skin Cancer took place in 2011, it has attracted more than 500 participants each year from all over the world. The interactive congress offers a comprehensive overview on all new developments in skin cancer and in particular melanoma therapy and a direct communication with the world´s leading experts in these fields. After being held as a joint meeting with the 8th World Congress on Melanoma and the 10th EADO annual conference 2013 in Hamburg, the congress will return to its origins in Munich in June 2014. Presently there is an exciting time for the development of new drugs for skin cancer/melanoma treatments. New immunotherapies, selective kinase inhibitors, new vaccines, and other innovative strategies for the intratumoral and systemic use are under development and are approaching the market for melanoma rapidly. Some have already been approved in the recent years. Non-melanoma skin cancer has become an exciting arena for clinical research as well. Several new drugs as hedgehog inhibitors for basal cell carcinomas are currently used in the routine and in innovative trials. However, it will be the main target for all of us to choose the right patients for the right drugs! The aim of the Interdisciplinary Global Conference on Developing New Treatments for Melanoma/Skin Cancer in Munich is to grant a deep overall insight into the development of new drugs for melanoma. The lively interaction of clinicians, as well as experts in translational and basic research, and representatives of the pharmaceutical industry, guarantees a successful outcome for every participant. International key opinion leaders on melanoma, non-melanoma skin cancer and cutaneous lymphomas are invited to give an overview throughout specified presentations, to present latest clinical trial results, and to discuss on exciting new drugs with the audience. In addition to the scientific value of this meeting, every participant may seize the given opportunity to interact with experts in a familiar setting in one of the most interesting cities of Germany. We look forward to welcoming you in Munich in June 2014! Axel Hauschild, MD Congress President Claus Garbe, MD Congress President 3 FINAL PROGRAM AT A GLANCE THURSDAY, JUNE 26TH ROYAL BALLROOM FRIDAY, JUNE 27TH R1+R2 ROYAL BALLROOM 8:00 8:00 9:00 9:00 10:00 10:00 R1+R2 SYMPOSIUM IV New drugs and trials: An update on immunotherapy and chemotherapy PARALLEL SESSION I New developments in melanoma diagnostics COFFEE BREAK POSTER PRICE KEY NOTE LECTURE 11:00 11:00 Opening of the industrial exhibition (with lunch) 12:00 12:00 Opening of the conference SYMPOSIUM I My personal highlights at ASCO 2014 13:00 14:00 COFFEE BREAK SATELLITE SYMPOSIUM I (gold sponsor) Malignant melanoma: What keeps us challenged – what motivates us? 15:00 SYMPOSIUM V New drugs and trials: An update on targeted agents and combo treatment FREE COMMUNICATIONS COFFEE BREAK 16:00 16:00 COFFEE BREAK SATELLITE SYMPOSIUM II (gold sponsor) Metastatic melanoma management: Translating the science to clinical practice 17:00 SYMPOSIUM III Mechanisms of resistance in tyrosine kinase inhibitor treatments 18:00 SATELLITE SYMPOSIUM IV with lunch (gold sponsor) Clinical perspectives on the expanding role of immuno-oncology within melanoma 15:00 SYMPOSIUM II National guidelines: How we treat stage III and IV melanoma 17:00 SATELLITE SYMPOSIUM III (gold sponsor) ASCO 2014 update: Are we ready for a personalized approach in malignant melanoma management? COFFEE BREAK 13:00 14:00 PARALLEL SESSION II Management of adverse events from new drugs SATELLITE SYMPOSIUM V (further sponsor) Advancing oncolytic immunotherapy SYMPOSIUM VI Rationale for sequential treatment algorithms: Which drug first, which drug thereafter? 18:00 CLOSING REMARKS SYMPOSIUM 4 SATELLITE SYMPOSIUM KEY NOTE LECTURE PARALLEL SESSION FREE COMMUNICATIONS 5 THURSDAY, JUNE 26TH 11:00 OPENING OF THE INDUSTRIAL EXHIBITION (with lunch) 12:00 OPENING OF THE CONFERENCE ROYAL BALLROOM CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY EADO presidential address Jean Jacques Grob, Marseille, France 12:10 –14:00 SYMPOSIUM I My personal highlights at ASCO 2014 ROYAL BALLROOM CHAIRPERSONS: CELESTE LEBBÉ, PARIS, FRANCE PAOLO ANTONIO ASCIERTO, NAPLES, ITALY 12:10 –12:32 12:38 –13:00 13:06 –13:28 13:34 –13:56 … in melanoma diagnostics Ralf Gutzmer, Hannover, Germany … in immunotherapy Reinhard Dummer, Zurich, Switzerland … in targeted therapies Grant McArthur, Melbourne, Australia … in non melanoma skin cancer Rainer Kunstfeld, Vienna, Austria 14:00 –14:15 COFFEE BREAK 14:15 –15:15 SATELLITE SYMPOSIUM I (gold sponsor) Malignant melanoma: What keeps us challenged – ROYAL BALLROOM what motivates us? MODERATOR: JONATHAN HOARE, LONDON, UNITED KINGDOM Discussants: Grant McArthur, Melbourne, Australia; Paul Lorigan, Manchester, UK; Jeffrey Sosman, Nashville, USA; Axel Hauschild, Kiel, Germany 14:15 –14:30 14:30 –15:15 6 New Molecules under development: What can we expect? Vladan Antic, Basel, Switzerland Current challenges in treating advanced melanoma – a panel discussion All participants, moderated by Jonathan Hoare, London, United Kingdom THURSDAY, JUNE 26TH 15:15 –16:15 SYMPOSIUM II National guidelines: How we treat stage III and IV melanoma ROYAL BALLROOM CHAIRPERSONS: HUBERT PEHAMBERGER, VIENNA, AUSTRIA ALESSANDRO TESTORI, MILAN, ITALY 15:15 –15:27 15:30 –15:42 15:45 –15:57 16:00 –16:12 … in Australia Grant McArthur, Melbourne, Australia … in Germany Michael Weichenthal, Kiel, Germany … in France Jean Jacques Grob, Marseille, France … in the United Kingdom Paul Lorigan, Manchester, United Kingdom 16:15 –16:30 COFFEE BREAK 16:30 –17:30 SATELLITE SYMPOSIUM II (gold sponsor) Metastatic melanoma management: Translating the science ROYAL BALLROOM to clinical practice CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY 16:30 –16:35 16:35 –17:15 17:15 –17:30 Chair’s introduction: Evolving treatment paradigms in BRAF V600-mutant metastatic melanoma Axel Hauschild, Kiel, Germany Patient-centred therapy decisions and targeted therapy optimisation James Larkin, London, United Kingdom Christoph Höller, Vienna, Austria Ask the experts: Your questions answered Chair’s summary Axel Hauschild, Kiel, Germany 17:30 –18:30 SYMPOSIUM III Mechanisms of resistance in tyrosine kinase inhibitor treatments ROYAL BALLROOM CHAIRPERSONS: ALEXANDER EGGERMONT, PARIS, FRANCE DIRK SCHADENDORF, ESSEN, GERMANY 17:30 –17:46 17:50 –18:06 18:10 –18:26 Resistance to kinase inhibitors: Mechanisms – what’s new? Grant McArthur, Melbourne, Australia Resistance to kinase inhibitors: Tumor microenvironment – a critical determinant? Reinhard Dummer, Zurich, Switzerland Resistance to kinase inhibitors: Brain metastases – a special challenge? Friedegund Meier, Tuebingen, Germany 7 FRIDAY, JUNE 27TH 08:00 –10:00 SYMPOSIUM IV New drugs and trials: An update on immunotherapy ROYAL BALLROOM and chemotherapy CHAIRPERSONS: STEPHAN GRABBE, MAINZ, GERMANY MICHELE MAIO, SIENA, ITALY 08:00– 08:10Ipilimumab Michele Maio, Siena, Italy 08:12– 08:22Nivolumab Jedd Wolchok, New York, USA 08:24– 08:34MK-3475 Dirk Schadendorf, Essen, Germany 08:36– 08:46 Biomarkers for PD-1 response Helen Gogas, Athens, Greece 08:48– 08:58IL19 Thomas Eigentler, Tuebingen, Germany 09:00– 09:10 MAGE-A3 ASCI Brigitte Dreno, Nantes, France 09:12– 09:22T-VEC Jürgen Becker, Graz, Austria 09:24– 09:34PV-10 Vernon Sondak, Tampa, USA 09:36– 09:46Electroporation Adil I. Daud, San Francisco, USA 09:48– 09:58Nab-paclitaxel Axel Hauschild, Kiel, Germany 09:00 –10:00 PARALLEL SESSION I New developments in melanoma diagnostics R1+R2 CHAIRPERSONS: JESSICA HASSEL, HEIDELBERG, GERMANY ALEXANDER RÖSCH, HOMBURG, GERMANY 09:00– 09:16 09:20– 09:36 09:40– 09:56 8 Mutational testings of melanoma Jessica Hassel, Heidelberg, Germany Imaging of primary melanoma Josep Malvehy, Barcelona, Spain Molecular diagnostics in melanoma Jürgen Bauer, Tuebingen, Germany FRIDAY, JUNE 27TH 10:00 –10:25 COFFEE BREAK 10:25 –10:30 POSTER PRICE ROYAL BALLROOM Claus Garbe, Tuebingen, Germany 10:30 –11:30KEY NOTE LECTURE ROYAL BALLROOM CHAIRPERSON: ROLAND KAUFMANN, FRANKFURT, GERMANY 10:30– 11:00 11:00– 11:30 Targeted treatment of extracutaneous melanoma Jeffrey Sosman, Nashville, USA The future of immunotherapy Jedd Wolchok, New York, USA 10:30 –11:30 PARALLEL SESSION II Management of adverse events from new drugs R1+R2 CHAIRPERSONS: CELESTE LEBBÉ, PARIS, FRANCE SANJIV AGARWALA, BETHLEHEM, USA 10:30 –10:46 10:50 –11:06 11:10 –11:26 Skin cancer development and kinase inhibitors Celeste Lebbé, Paris, France Immunotherapy-induced adverse events Katharina Kähler, Kiel, Germany Photosensitivity: How I manage it Mark Berneburg, Regensburg, Germany 11:30 –12:30 SATELLITE SYMPOSIUM III (gold sponsor) ASCO 2014 update: Are we ready for a personalized ROYAL BALLROOM approach in malignant melanoma management? CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY 11:30 –11:40 11:40 –12:00 12:00 –12:20 12:20 –12:30 Introduction and ASCO highlights in malignant melanoma Axel Hauschild, Kiel, Germany What was learned at ASCO? Sanjiv Agarwala, Bethlehem, USA What we have to learn after ASCO? Richard Kefford, Sydney, Australia Panel discussion and conclusions 9 FRIDAY, JUNE 27TH 12:30 –13:00 COFFEE BREAK 13:00 –14:00 SATELLITE SYMPOSIUM IV with lunch (gold sponsor) Clinical perspectives on the expanding role of immuno-oncology ROYAL BALLROOM within melanoma CHAIRPERSON: JEAN JACQUES GROB, MARSEILLE, FRANCE 13:00 –13:05 Chair’s welcome and introduction Jean Jacques Grob, Marseille, France 13:05 –13:20 What’s best for first in line for the fight against metastatic melanoma? Dirk Schadendorf, Essen, Germany 13:20 –13:35 13:35 –13:55 13:55 –14:00 Adjuvant melanoma treatment benefits: How can we get there? Jean Jacques Grob, Marseille, France Setting the standard, raising the bar Jedd Wolchok, New York, USA Concluding remarks Jean Jacques Grob, Marseille, France 14:00 –15:30 SYMPOSIUM V ROYAL BALLROOM New drugs and trials: An update on targeted agents and combo treatment CHAIRPERSONS: CAROLA BERKING, MUNICH, GERMANY PETER MOHR, BUXTEHUDE, GERMANY 14:00 –14:10 Dabrafenib and trametinib Jean Jacques Grob, Marseille, France 14:13 –14:23 Vemurafenib and cobimetinib Grant McArthur, Melbourne, Australia 14:26 –14:36LGX818 Carola Berking, Munich, Germany 14:39 –14:49 cKIT inhibitors Ralf Gutzmer, Hannover, Germany 14:52 –15:02 NRAS inhibitors Paolo Antonio Ascierto, Naples, Italy 15:05 –15:15 Chemosensitivity-directed therapy Selma Ugurel, Wuerzburg, Germany 15:18 –15:28 Chemosaturation in liver metastasis Vernon Sondak, Tampa, USA 10 FRIDAY, JUNE 27TH 14:00 –15:15 FREE COMMUNICATIONS R1+R2 CHAIRPERSONS: THOMAS EIGENTLER, TUEBINGEN, GERMANY LIDIJA KANDOLF-SEKULOVIC, BELGRADE, SERBIA 14:00 –14:08Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma Adil Daud, San Francisco, USA 14:11 –14:19UBE2C as a potential therapeutic target gene for BRAF resistant melanoma Richard Essner, Los Angeles, USA 14:22 –14:30Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal cell carcinoma (BCC) Ralf Gutzmer, Hannover, Germany 14:33 –14:41Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib Heike Niessner, Tuebingen, Germany 14:44 –14:52Beta-catenin in the course of aquired resistance to the BRAFV600E inhibitor vemurafenib in malignant melanoma Tobias Sinnberg, Tuebingen, Germany 14:55 –15:03Sentinel node biopsy performed with local anesthesia: Our experience at European Institute of Oncology Alessandro Testori, Milan, Italy 15:06 –15:14Indications for sentinel lymph node biopsy: Through thick and thin John Vetto, Portland, USA 15:30 –16:00 COFFEE BREAK 11 FRIDAY, JUNE 27TH 16:00 –17:00 SATELLITE SYMPOSIUM V (further sponsor) Advancing oncolytic immunotherapy ROYAL BALLROOM CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY 16:00 –16:05 16:05 –16:25 16:25 –16:50 16:50 –17:00 Introduction Axel Hauschild, Kiel, Germany Oncolytic immunotherapy – a local and systemic antitumor approach Jürgen Becker, Graz, Austria The oncolytic virus talimogene laherparepvec – clinical experience in melanoma Robert Andtbacka, Salt Lake City, USA The potential role of oncolytic immunotherapy in melanoma – a discussion Axel Hauschild, Kiel, Germany 17:00 –18:25 SYMPOSIUM VI Rationale for sequential treatment algorithms: ROYAL BALLROOM Which drug first, which drug thereafter? CHAIRPERSONS: GRANT MCARTHUR, MELBOURNE, AUSTRALIA CLAUS GARBE, TUEBINGEN, GERMANY 17:00 –17:25 17:30 –17:55 18:00 –18:20 Kinase inhibitors first Jeffrey Sosman, Nashville, USA Immunotherapy first Christoph Höller, Vienna, Austria Round Table Discussion Claus Garbe, Christoph Höller, Grant McArthur, Jeffrey Sosman 18:25 –18:30 CLOSING REMARKS ROYAL BALLROOM 12 Claus Garbe, Tuebingen, Germany CONGRESS FACULTY Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke’s Cancer Center Bethlehem, PA, USA Phone: +1 610 2970169 E-Mail: agarwas@slhn.org Robert Andtbacka, MD Associate Professor of Surgical Oncology Department of Surgery University of Utah Huntsman Cancer Institute 2000 Circle of Hope Drive Salt Lake City, Utah 84112-5550, USA Phone: +1 801 587 8808 E-Mail: Robert.Andtbacka@hci.utah.edu Paolo Antonio Ascierto, MD Unit of Medical Oncology and Innovative Therapies National Cancer Institute Via M. Semmola 80131 Naples, Italy Phone: +39 6 30154227 E-Mail: paolo.ascierto@gmail.com Adil I. Daud, MD Clinical Professor of Medicine and Co-Director of the Melanoma Program, UCSF Melanoma Center 1600 Divisadero St., Fourth Floor San Francisco, CA 94115, USA Phone: +1 415 353 7382 E-Mail: adaud@medicine.ucsf.edu Stephan Grabbe, MD Professor of Dermatology Director Department of Dermatology Johannes Gutenberg University Langenbeckstraße 1 55131 Mainz, Germany Phone: +49 6131 172910 E-Mail: stephan.grabbe@ukmainz.de Brigitte Dréno, MD Professor of Dermatology Department of Dermatology University of Nantes CHU Nantes Place Alexis Ricordeau 44093 Cedex 01, France Phone: +33 240 083118 E-Mail: brigitte.dreno@wanadoo.fr Jean Jacques Grob, MD Professor of Dermatology Service de Dermatology and Cancer Research Hopital de la Timone 264 Rue St Pierre 13885 Marseille CEDEX 05, France Phone: +33 491 388591 E-Mail: jean-jacques.grob@ap-hm.fr Reinhard Dummer, MD Professor of Dermatology Department of Dermatology Universitätsspital Zurich Gloriastrasse 31 8091 Zurich, Switzerland Phone: +41 44 2552507 E-Mail: reinhard.dummer@usz.ch Ralf Gutzmer, MD Professor of Dermatology Department of Dermatology Hannover Medical School Hauttumorzentrum Ricklingerstraße 5 30449 Hannover, Germany Phone: +49 511 9246-0 E-Mail: gutzmer.ralf@mh-hannover.de Jürgen Bauer, MD Professor of Dermatology Department of Dermatology Eberhard Karls University Liebermeister Straße 25 72076 Tuebingen, Germany Phone: +49 7071 2984585 E-Mail: juergen.bauer@med. uni-tuebingen.de Alexander M. M. Eggermont, MD, PhD Professor of Surgery Directeur Général, Institut de Cancérologie Gustave Roussy 114 Rue Edouard Vaillant 94800 Villejuif/Paris, France Phone: +33 142 114016 E-Mail: alexander.eggermont@igr.fr Jürgen Becker, MD Professor of Dermatology Department of Dermatology Medical University of Graz Auenbruggerplatz 8 8036 Graz, Austria Phone: +49 316 385 12538 E-Mail: juergen.becker@meduni-graz.at Thomas Eigentler, MD Department of Dermatology Eberhard Karls University Liebermeister Straße 25 72076 Tuebingen, Germany Phone: +49 7071 2985748 E-Mail: thomas.eigentler@med. uni-tuebingen.de Carola Berking, MD Professor of Dermatology Department of Dermatology Ludwig Maximilians University Frauenlobstraße 9–11 80337 Munich, Germany Phone: +49 89 51476010 E-Mail: carola.berking@med.unimuenchen.de Claus Garbe, MD Professor of Dermatology Department of Dermatology Eberhard Karls University Liebermeister Straße 25 72076 Tuebingen, Germany Phone: +49 7071 2987110 E-Mail: claus.garbe@med. uni-tuebingen.de Christoph Höller, MD Professor of Dermatology Department of Dermatology University of Vienna Währinger Gürtel 18-20 1090 Vienna, Austria Phone: +43 1 40400 4786/7700 E-Mail: christoph.hoeller@meduniwien.ac.at Mark Berneburg, MD Professor of Dermatology University Hospital Regensburg Franz-Josef-Strauß-Allee 11 93053 Regensburg, Germany Phone: +49 941 9449601 E-Mail: sekretariat.derma@ukr.de Helen Gogas, MD Professor of Oncology Medical School, University of Athens 24 Karneadou STR Athens 10675, Greece Phone: +30 69 44 68 1159 E-Mail: hgogas@hol.gr Katharina Kähler, MD Department of Dermatology University of Kiel Schittenhelmstraße 7 24105 Kiel, Germany Phone: +49 431 5971512 E-Mail: kckaehler@yahoo.de Jessica Hassel, MD Department of Dermatology University of Heidelberg Im Neuenheimer Feld 440 69120 Heidelberg, Germany Phone: +49 6221 568562 E-Mail: jessica.hassel@med.uniheidelberg.de Axel Hauschild, MD Professor of Dermatology Department of Dermatology University of Kiel Schittenhelmstraße 7 24105 Kiel, Germany Phone: +49 431 5971852 E-Mail: ahauschild@dermatology.uni-kiel.de 13 Michele Maio, MD Professor of Oncology Department of Oncology University Hospital of Siena Strada delle Scotte n° 14 53100 Siena, Italy Phone: +39 0577 586336 E-Mail: mmaio@cro.it Dirk Schadendorf, MD Professor of Dermatology Director, Department of Dermatology University Hospital Essen Hufelandstraße 55 45147 Essen, Germany Phone: +49 201 7232430 E-Mail: dirk.schadendorf@uk-essen.de Roland Kaufmann, MD Professor of Dermatology, Director Department of Dermatology Clinical Center J. W. Goethe University Theodor-Stern-Kai 7 60590 Frankfurt, Germany Phone: +49 69 63015311 E-Mail: kaufmann@em.uni-frankfurt.de Josep Malvehy, MD Coordinator of the Melanoma Unit Hospital Clínico de Barcelona C/Villarroel 170.08036 Barcelona, Spain Phone: +34 93 22754002422 E-Mail: jmalvehy@clinic.ub.es Richard Kefford, MD Professor of Medicine Westmead Millennium Institute for Medical Research C24 - Westmead Hospital The University of Sydney NSW 2006 Australia Phone: +61 2 9845 8089 E-Mail: richard.kefford@sydney.edu.au Grant McArthur, MD Professor of Medicine Head Cancer Therapeutics Program Head Skin and Melanoma Service Divisions of Cancer Medicine and Research Peter MacCallum Cancer Centre Locked Bag 1A’Beckett St Melbourne 8006, Australia Phone: +61 3 9656 1954 E-Mail: grant.mcarthur@petermac.org Vernon Sondak, MD Professor of Surgery Chief, Division of Cutaneous Oncology Director of Surgical Education H. Lee Moffitt Cancer Center and Research Institute 12902 Magnolia Drive Tampa FL 33612, USA Phone: +1 813 7458788 E-Mail: vernon.sondak@moffitt.org Lidija Kandolf-Sekulovic, MD Department of Dermatology Military Medical Academy 17 Crnotravska 11000 Belgrade, Serbia Phone: +381 113608583 E-Mail: lkandolfsekulovic@gmail.com Rainer Kunstfeld, MD Professor of Dermatology Department of Dermatology University of Vienna Währinger Gürtel 18–20 1090 Vienna, Austria Phone: +43 1 40400-6262 E-Mail: rainer.kunstfeld@meduniwien.ac.at James Larkin, MD The Royal Marsden Hospital Fulham Road London SW3 6JJ, United Kingdom Phone: +44 207 808 8576, UK E-Mail: james.larkin@rmh.nhs.uk Celeste Lebbé, MD Professor of Dermatology Department of Dermatology Hôpital Saint-Louis 1, Avenue Claude-Vellefaux 75010 Paris, France Phone: +33 142 499961 E-Mail: celeste.lebbe@sls.aphp.fr Paul Lorigan, MD, FRCP Senior Lecturer and Consultant in Medical Oncology School of Cancer and Imaging Sciences University of Manchester c/o The Christie NHS Foundation Trust Wilmslow Road, Withington Manchester M20 4BX, UK Phone: +44 161 446 8002 E-Mail: paul.lorigan@christie.nhs.uk 14 Friedegund Meier, MD Professor of Dermatology Department of Dermatology Eberhard Karls University Liebermeister Straße 25 74076 Tuebingen, Germany Phone: +49 7071 2984500 E-Mail: friedegund.meier@ med.uni-tuebingen.de Peter Mohr, MD Center of Dermatology Elbeklinikum Buxtehude Am Krankenhaus 1 21614 Buxtehude, Germany Phone: +49 4161 7036209/-6250 E-Mail: peter.mohr@elbekliniken.de Hubert Pehamberger, MD Professor of Dermatology Director, Department of Dermatology Medical University of Vienna Vienna General Hospital Währinger Gürtel 18–20 1090 Vienna, Austria Phone: +43 1 404007710 E-Mail: hubert.pehamberger@ meduniwien.ac.at Alexander Roesch, MD Professor of Dermato-Oncology University Hospital Essen Hufelandstr. 55 45122 Essen, Germany E-Mail: alexander.roesch@uk-essen.de Jeffrey A. Sosman, MD Professor of Medicine Ingram Professor for Cancer Research Vanderbilt University Medical Center Division of Hematology/Oncology 777 PRB, 2220 Pierce Avenue Nashville, TN 37232, USA Phone: +1 615 343 6653 E-Mail: jeff.sosman@vanderbilt.edu Alessandro Testori, MD Director Melanoma and muscle-cutaneous sarcomas Division Istituto Europeo di Oncologia Via Ripamonti 435 20141 Milan, Italy Phone: +39 0257489459-493-958 E-Mail: alessandro.testori@ieo.it Selma Ugurel, MD Professor of Dermatology Department of Dermatology Julius-Maximilians University of Würzburg Josef-Schneider-Strasse 2 97080 Würzburg, Germany Phone: +43 676 4531140 E-Mail: Ugurel_S@klinik.uni-wuerzburg.de Michael Weichenthal, MD Professor of Dermatology Department of Dermatology University of Kiel Schittenhelmstr.7 24105 Kiel, Germany Phone: +49 431 597 1537 E-Mail: mweichenthal@dermatology. uni-kiel.de Jedd Wolchok, MD, PhD Memorial Sloan Kettering Cancer Center 1275 York Avenue New York, NY 10065, USA Phone: +1 646 888 2315 E-Mail: wolchokj@mskcc.org SATELLITE SYMPOSIA OVERVIEW THURSDAY, JUNE 26TH 4:15 –15:15 SATELLITE SYMPOSIUM I 1 Roche (gold sponsor) ROYAL BALLROOM 6:30 –17:30 SATELLITE SYMPOSIUM II 1 GlaxoSmithKline (gold sponsor) ROYAL BALLROOM FRIDAY, JUNE 27TH 1:30 –12:30 SATELLITE SYMPOSIUM III 1 Merck/MSD (gold sponsor) ROYAL BALLROOM 3:00 –14:00 SATELLITE SYMPOSIUM IV 1 Bristol-Myers Squibb (gold sponsor) ROYAL BALLROOM 6:00 –17:00 SATELLITE SYMPOSIUM V 1 Amgen (further sponsor) ROYAL BALLROOM Gold Sponsorship includes: –Satellite Symposium –Booth –Bag insert –5 complimentary registrations –Hyperlinked logo on congress website –Presentation of company logo in event materials Bronze Sponsorship includes: –Advertised as sponsor of one coffee break during one congress day –1 brochure on display –3 complementary registrations –Logo on first page of congress website –Presentation of company logo in all event materials 15 GSK Satellite Symposium Metastatic Melanoma Management: Translating the Science to Clinical Practice Venue: Leonardo Royal Hotel Munich Room: Royal Ballroom Date: Thursday 26 June 16:30–17:30 NOW LICENSED Learn more about TAFINLAR® from experts Interact with leading global melanoma experts as they discuss making patient-focused treatment decisions and their experience with TAFINLAR® in the clinic. GSK contributed to speaker selection and agenda development. A NEW first-line BRAF inhibitor Treatment with TAFINLAR® was proven to significantly extend progression-free survival (PFS) vs dacarbazine1 Efficacy in previously untreated patients (BREAK-3 trial)1 ▼ PFS median, months (95% CI) Hazard ratio (95% CI) TAFINLAR® (n=187) Dacarbazine (n=63) 6.9 2.7 (5.2, 9.0) (1.5, 3.2) 0.37 (0.24, 0.58) p <0.0001 6.9 months Median PFS with TAFINLAR® Investigator assessment, 25 Jun 2012, secondary data cutoff subsequent to primary data cutoff on 19 Dec 2011. TAFINLAR® is indicated in monotherapy for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation ■ Before taking TAFINLAR®, patients must have confirmation of tumour BRAF V600 mutation using a validated test Note: Congress and associated information, exhibitions, etc, are intended for the benefit of oncology professionals. The safety profile is based on data from 5 clinical monotherapy studies and included 578 patients with melanoma. The most frequently occurring adverse reactions (≥15%) of any grade for TAFINLAR® included hyperkeratosis, headache, pyrexia, arthralgia, fatigue, nausea, papilloma, alopecia, rash and vomiting.1 TAFINLAR® can also cause serious, less common side effects, including increasing the risk of developing new primary cutaneous malignancies, serious febrile drug reactions, uveitis and iritis, and embryofoetal toxicity.1 Prescribing Information (Please refer to full SmPC before prescribing) TAFINLAR®▼(dabrafenib) 50mg and 75mg capsules. Each capsule contains dabrafenib mesilate, equivalent to 50mg and 75mg of dabrafenib, respectively. Indication In monotherapy for adults with unresectable or metastatic melanoma with a BRAF V600 mutation. Dosage and administration Before taking dabrafenib, patients must have confirmation of BRAF V600 mutation using a validated test. 150mg twice daily (b.d.) with interval of ~12hrs between doses (max. total daily dose 300mg), taken until patient no longer derives benefit or develops unacceptable toxicity. Take ≥1 hour before or ≥2 hours after a meal, at similar times every day. Swallow capsules whole with water; do not chew, crush or mix with food/liquids. If dose is missed, do not take if <6 hours until next dose. Dose modification: Management of ADRs may require treatment interruption, dose reduction or discontinuation. 1st reduction: 100mg b.d., 2nd reduction: 75 mg b.d., 3rd reduction: 50mg b.d. (min. dose). Consider dose re-escalation following same dosing steps as de-escalation when ADR under effective management. Renal impairment: No dose adjustment required in mild or moderate impairment. Caution advised in severe renal impairment. Hepatic impairment: No dose adjustment required in mild impairment. Caution advised in moderate and severe hepatic impairment. Elderly: No initial dose adjustment required in patients >65 yrs. Paediatrics: Safety & efficacy not established in patients <18 yrs. Contraindications Hypersensitivity to active substance or excipients. Special warnings and precautions Pyrexia: Interrupt treatment if temperature ≥38.5°C and investigate for infection. Restart once fever resolves with anti-pyretics. Restart at reduced dose if fever associated with other severe signs or symptoms as clinically appropriate. Cutaneous squamous cell carcinoma (CuSCC) and new primary melanoma: Examine skin prior to treatment, monthly during treatment and for up to 6 months after discontinuation. Patients should inform their physician immediately if a new lesion develops. Dose modifications/ interruptions not recommended. Non-cutaneous secondary/ recurrent malignancy: Head and neck examination and chest/abdominal scan prior to treatment. Monitor as clinically appropriate and for up to 6 months after discontinuation. Renal failure: Monitor serum creatinine routinely while on therapy, and interrupt treatment as clinically appropriate if creatinine increases. Uveitis: Monitor for signs and symptoms of ophthalmological reactions while on therapy. Pancreatitis: Investigate unexplained abdominal pain promptly, including serum amylase and lipase measurements. Monitor closely when re-starting dabrafenib. QT prolongation: Treatment not recommended in patients with uncorrectable electrolyte abnormalities, long QT syndrome or those taking medicinal products known to prolong QT interval. Monitor ECG and electrolytes before treatment, one month after therapy, and after dose modification. Permanent treatment discontinuation recommended if QTc increase is both >500msec and >60msec change from baseline. Undesirable effects Please refer to full SmPC before prescribing. Very common: Papilloma, decreased appetite, headache, cough, nausea, vomiting, diarrhoea, hyperkeratosis, alopecia, rash, PPE syndrome, arthralgia, myalgia, pain in extremity, pyrexia, fatigue, chills, asthenia. Common: cuSCC, seborrhoeic keratosis, skin tags, basal cell carcinoma, hypophosphataemia, hyperglycaemia, constipation, dry skin, pruritus, actinic keratosis, skin lesion, erythema, influenza-like illness, LVEF decrease. Interactions Avoid co-administration with strong inducers or inhibitors of CYP2C8 and CYP3A4, and agents that increase gastric pH, when possible. Exercise caution when co-administering with digoxin and with warfarin; consider additional INR monitoring. Dabrafenib may reduce efficacy of hormonal contraceptives; use alternative effective contraception and continue for 4 weeks postdiscontinuation. Pregnancy Do not administer to pregnant women unless benefit to mother outweighs the risk to foetus. Marketing authorisation (MA) nos. EU/1/13/865/001; EU/1/13/865/003. MA holder GlaxoSmithKline Trading Services Ltd., Kinsale Road, Cork. Legal category POM ONCE/BRF/0074/13 September 2013. Adverse events should be reported. For UK attendees: – Reporting forms and information can be found at: http://www.mhra.gov. uk/yellowcard – Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 For ex-UK attendees: – Please report adverse events via your local GSK contact or affiliate office Further information is available from: Customer Contact Centre, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT; customercontactuk@gsk.com; Freephone: 0800 221 441. Please see Summary of Product Characteristics for TAFINLAR®. Reference: 1. GlaxoSmithKline. TAFINLAR® Summary of Product Characteristics. ©2014 GlaxoSmithKline group of companies. All rights reserved. OF/DBF/0007/14 Date of preparation May 2014 TAFINLAR is a registered trademark of the GlaxoSmithKline group of companies. GENERAL INFORMATION Congress Venue Leonardo Royal Hotel Munich, Moosacher Straße 90, 80809 Munich Phone: +49 (0)89 2885380, E-Mail: info.royalmunich@leonardo-hotels.com www.leonardo-hotels.com/Leonardo_Royal_Hotel_Munich Congress Date June 26th–27th, 2014 Registration and Information Desk The registration desk is situated at the ground floor of the Leonardo Royal Hotel to the left of the reception. Registration Desk Opening Hours Wednesday, June 25th, 2014 17:00–20:00 (early check-in) Thursday, June 26th, 2014 08:00–20:00 Friday, June 27th, 2014 07:00–20:00 CME Credits The 4th European Post-Chicago Melanoma / Skin Cancer Meeting: Results and Interpretations of ASCO Presentations 2014: Interdisciplinary Global Conference on News in Melanoma / Skin Cancer is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. The 4th European Post-Chicago Melanoma / Skin Cancer Meeting: Results and Interpretations of ASCO Presentations 2014: Interdisciplinary Global Conference on News in Melanoma / Skin Cancer is designated for a maximum of 9 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/ internationalcme. Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. For German participants: This program has been accredited by the German Ministry of Health with 16 German credit points (category A, 6 points on Thursday, 10 points on Friday). How to receive your CME Credits To obtain CME credits please fill in the Evaluation Form, which you will find in your congress bag and in the meeting rooms. To get your Certificate of Attendance with the CME credits please return the Evaluation Form duly filled in to the registration desk. 18 Cancellation Policy Cancellations must be received in writing by May 1st, 2014. No refunds will be granted after that date. To cancel a registration, please send an email to mirja.christ@medconcept.org and include “European Post-Chicago Melanoma/Skin Cancer Meeting 2014 Cancellation” in the subject line. A processing fee of 30 Euro will be deducted from each cancelled registration. Substitutions (new ticket holder must come from the same institution) are possible and must be received in writing by June 11th, 2014. To substitute a registration please send an email including the name of the original registrant and the name of the person substituting to mirja.christ@medconcept.org and include “European Post-Chicago Melanoma/Skin Cancer Meeting 2014 Substitution” in the subject line. The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force, or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso. Exhibition A commercial exhibition will be held at the congress venue, close to the main meeting rooms. Exhibition Opening Hours Thursday, June 26th, 201411:30–18:30 Friday, June 27th, 2014 07:30–18:30 Language and Translation The official language of the meeting will be English. Simultaneous translation will not be provided. Insurance The Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect to health and travel insurance. Passport and Visa For most nationalities visas are not required for entering Germany. For further information about visa and passport please contact the German embassy in your country. If an invitation letter for visa purposes is required please contact MedConcept. Travel by Train Travel by train in comfort with 100 % green energy With the Deutsche Bahn from 99 Euro anywhere in Germany In cooperation with MedConcept GmbH and Deutsche Bahn, you can travel safely and environmental friendly by train to all MedConcept meetings. Deutsche Bahn guarantees to get the energy you need for your journey from 100 % renewable sources. Compared with a car, each journey by train spares the environment two-thirds CO2. Compared with a plane, even respectable 75 percent! The price for your event ticket for a return trip anywhere in Germany is: 2. Class 99 Euro 1. Class 159 Euro Terms and Conditions: ·Advanced booking of at least 3 days. ·Passengers restrict themselves to a particular train and travel times. ·Changes and reimbursement before the first day of validity are 15 Euro excluded from the first day of validity onwards. ·For a supplement of 40 Euro full flexible tickets without a restriction to a particular train and travel times are available. ·The service hotline of the Deutsche Bahn (+49 (0)1806 311153) is glad to inform you about ticket prices for international journeys. 19 How to book your event ticket For ticket reservation, call the service hotline +49 (0)1806 311 53 and quote “MedConcept” as reference. Please keep your credit card ready. The service hotline is available from Monday to Saturday 7:00 am to 10:00 pm. Calls within Germany will be charged at 0.20 Euro per call, the expenses from mobiles will be charged with 0.60 Euro per call at maximum. MedConcept and Deutsche Bahn wish you a pleasant journey! Congress Organization Gesellschaft für medizinische Projekte mbH Responsible congress organizer: Mrs. Mirja Christ Friedenstraße 58 · 15366 Neuenhagen bei Berlin mirja.christ@medconcept.org · www.medconcept.org Phone +49 (0)3342 42689-30 · Fax +49 (0)3342 42689-40 20 www.melanomaglobal2014.org SPONSORS GOLD 80,000 Euro Gold Sponsorship 10,000 Euro Provision of Lanyards and Company Logo on Participant Badge BRONZE FURTHER SPONSORS Celgene Corporation Delcath Systems medac Novartis Oncology 6,000 Euro Sponsoring OncoSec Medical Incorporated SciBase 21 PRINTED ON RECYCLING PAPIER 22 DESIGN UND DRUCK: MEDIASERVICE GMBH DRUCK UND KOMMUNIKATION · FOTOS: S8/9 ISTOCKPHOTO/MANFREDXY MÜNCHEN, GRASSIMO BAU MUENCHEN, KOUPTSOVA MÜNCHEN; FLICKR/DIGITAL CAT S13 ISTOCLPHOTO/SVEN PETER, SEEWHATMITCHSEE · S10/11 ISTOCKPHOTO/XYNO MÜNCHEN (2), ALEXM156MÜNCHEN; FLICKR ST. DAMENKAPELLE
